Coherus Oncology (CHRS) Net Equity Issued and Repurchased (2014 - 2026)

Coherus Oncology has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $53.6 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $53.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (changed N/A YoY) and the FY2024 annual result came in at $1.5 million, down 97.29% from the prior year.
• Net Equity Issued and Repurchased climbed to $53.6 million in Q1 2026 per CHRS's latest filing, from -$52000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $53.6 million in Q1 2026 and troughed at -$52000.0 in Q2 2024.
• A 3-year average of $21.7 million and a median of $6.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 77.95% in 2024, down 100.11% in 2024.
• Over 3 years, Net Equity Issued and Repurchased stood at $46.8 million in 2023, then sank by 100.11% to -$52000.0 in 2024, then surged by 103273.08% to $53.6 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $53.6 million, -$52000.0, and $1.5 million for Q1 2026, Q2 2024, and Q1 2024 respectively.